Nutritional Intervention for Amyotrophic Lateral Sclerosis
Overview
Nutritional Sciences
Authors
Affiliations
Aim: The aim of the study was to assess the consequences of early and systematic nutritional intervention on the clinical conditions of amyotrophic lateral sclerosis (ALS) patients and on the opportunity to maintain a good nutritional status for as long as possible.
Methods: Thirty-three subjects with ALS. Protocol Group: 12 subjects (9 M and 3 F) monitored according to a precise nutritional intervention protocol.
Control Group: BMI (kg/m2) 23.6 ± 4.1 vs. 21.6 ± 3.5; weight loss as a percentage of usual weight 6.6 ± 7.9 vs. 16.3 ± 8.8 (P=0.003). At six months: weight loss as a percentage of usual weight 4.9 ± 6.2 vs. 16.9 ± 10.2 (P=0.002). At 12 months: weight loss as a percentage of usual weight 7.3 ± 7.1 vs. 17.5 ± 11.1 (P=0.03). At the first follow-up visit, fewer patients in the Protocol Group were receiving enteral nutrition (25%) than patients in the CONTROL GROUP (60%). At six-month follow-up visit: 30% vs. 68%. Standard enteral nutrition formulas were used. One year after initial assessment, the mortality rate was 17% for the Protocol Group, whereas it was 24% at six months and 33% after one year for the CONTROL GROUP.
Results: Data recorded at the time of initial assessment were compared and expressed as the mean ± standard deviation for the Protocol Group vs. the
Conclusion: If patients are treated before any significant weight loss occurs, early and specific nutritional intervention allows good nutritional status to be maintained for a longer period; if artificial nutrition is required, standard diets are able to ensure adequate clinical results.
Paraoxonase I Activity and Its Relationship with Nutrition in Amyotrophic Lateral Sclerosis.
Proano B, Benlloch M, Sancho-Castillo S, Privado J, Bargues-Navarro G, Sanchis-Sanchis C Antioxidants (Basel). 2024; 13(8).
PMID: 39199265 PMC: 11351986. DOI: 10.3390/antiox13081021.
Baldwin C, de van der Schueren M, Kruizenga H, Weekes C Cochrane Database Syst Rev. 2021; 12:CD002008.
PMID: 34931696 PMC: 8691169. DOI: 10.1002/14651858.CD002008.pub5.
Lopez-Gomez J, Ballesteros-Pomar M, Torres-Torres B, Pintor-de la Maza B, Penacho-Lazaro M, Palacio-Mures J Nutrients. 2021; 13(8).
PMID: 34444925 PMC: 8401888. DOI: 10.3390/nu13082765.
Energy Balance as a Moderator of Neurologic Disease Risk and Progression.
Smith Jr D, Pavela G Neurotox Res. 2020; 38(1):242-248.
PMID: 32215816 PMC: 8593878. DOI: 10.1007/s12640-020-00190-4.